---
input_text: rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments
  and an Extended Pathology Beyond the Central Nervous System. Aspartoacylase (AspA)
  gene mutations cause the pediatric lethal neurodegenerative Canavan disease (CD).
  There is emerging promise of successful gene therapy for CD using recombinant adeno-associated
  viruses (rAAVs). Here, we report an intracerebroventricularly delivered AspA gene
  therapy regime using three serotypes of rAAVs at a 20-fold reduced dose than previously
  described in AspA(-/-) mice, a bona-fide mouse model of CD. Interestingly, central
  nervous system (CNS)-restricted therapy prolonged survival over systemic therapy
  in CD mice but failed to sustain motor functions seen in systemically treated mice.
  Importantly, we reveal through histological and functional examination of untreated
  CD mice that AspA deficiency in peripheral tissues causes morphological and functional
  abnormalities in this heretofore CNS-defined disorder. We demonstrate for the first
  time that AspA deficiency, possibly through excessive N-acetyl aspartic acid accumulation,
  elicits both a peripheral and CNS immune response in CD mice. Our data establish
  a role for peripheral tissues in CD pathology and serve to aid the development of
  more efficacious and sustained gene therapy for this disease.
raw_completion_output: |-
  primary_disease: Canavan disease (CD)

  medical_actions: intracerebroventricularly delivered AspA gene therapy; histological examination; functional examination

  symptoms: immune impairments; extended pathology beyond the Central Nervous System; morphological abnormalities; functional abnormalities; excessive N-acetyl aspartic acid accumulation

  chemicals: recombinant adeno-associated viruses (rAAVs); N-acetyl aspartic acid

  action_annotation_relationships: intracerebroventricularly delivered AspA gene therapy TREATS immune impairments IN Canavan disease (CD); intracerebroventricularly delivered AspA gene therapy (with recombinant adeno-associated viruses) TREATS extended pathology beyond the Central Nervous System IN Canavan disease (CD); histological examination IDENTIFIES morphological abnormalities IN Canavan disease (CD); functional examination IDENTIFIES functional abnormalities IN Canavan disease (CD); excessive N-acetyl aspartic acid accumulation CAUSES immune impairments IN Canavan disease (CD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  excessive N-acetyl aspartic acid accumulation CAUSES immune impairments IN Canavan disease (CD)

  ===

extracted_object:
  primary_disease: MONDO:0016063
  medical_actions:
    - intracerebroventricularly delivered AspA gene therapy
    - MAXO:0000144
    - functional examination
  symptoms:
    - immune impairments
    - extended pathology beyond the Central Nervous System
    - morphological abnormalities
    - functional abnormalities
    - excessive N-acetyl aspartic acid accumulation
  chemicals:
    - recombinant adeno-associated viruses (rAAVs)
    - N-acetyl aspartic acid
  action_annotation_relationships:
    - subject: intracerebroventricularly delivered AspA gene therapy
      predicate: TREATS
      object: immune impairments
      qualifier: MONDO:0016063
      subject_qualifier: intracerebroventricularly delivered
      subject_extension: AspA gene therapy
    - subject: intracerebroventricularly delivered AspA gene therapy (with recombinant
        adeno-associated viruses)
      predicate: TREATS
      object: extended pathology beyond the Central Nervous System
      qualifier: MONDO:0010079
      subject_qualifier: intracerebroventricularly delivered
      subject_extension: AspA gene therapy
      object_extension: extended pathology beyond the Central Nervous System
    - subject: MAXO:0000144
      predicate: IDENTIFIES
      object: morphological abnormalities
      qualifier: MONDO:0010079
    - subject: functional examination
      predicate: IDENTIFIES
      object: functional abnormalities
      qualifier: MONDO:0016063
    - subject: excessive accumulation
      predicate: CAUSES
      object: immune impairments
      qualifier: MONDO:0016063
      subject_extension: N-acetyl aspartic acid
named_entities:
  - id: MONDO:0010079
    label: Canavan disease
  - id: MONDO:0003847
    label: Genetic disorders
  - id: HP:0000739
    label: Anxiety
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:16953
    label: N-acetyl-L-aspartate
  - id: CHEBI:76720
    label: antisense oligonucleotide
  - id: MONDO:0019052
    label: Inborn errors of metabolism (IEM)
  - id: CHEBI:35584
    label: Purines
  - id: CHEBI:16898
    label: Pyrimidines
  - id: CHEBI:35692
    label: Dicarboxylic acids
  - id: CHEBI:16040
    label: Cytosine
  - id: CHEBI:17562
    label: Cytidine
  - id: CHEBI:16737
    label: Creatinine
  - id: CHEBI:17568
    label: Uracil
  - id: CHEBI:16704
    label: Uridine
  - id: CHEBI:17802
    label: Beta-pseudouridine
  - id: CHEBI:16708
    label: Adenine
  - id: CHEBI:38635
    label: 3-methyladenine
  - id: CHEBI:17368
    label: Hypoxanthine
  - id: CHEBI:15318
    label: Xanthine
  - id: CHEBI:18107
    label: Xanthosine
  - id: CHEBI:17596
    label: Inosine
  - id: CHEBI:16750
    label: Guanosine
  - id: CHEBI:22652
    label: Ascorbic acid
  - id: CHEBI:17821
    label: Thymine
  - id: CHEBI:17748
    label: Thymidine
  - id: CHEBI:27226
    label: Uric acid
  - id: CHEBI:68441
    label: 1-methyluric acid
  - id: CHEBI:16742
    label: Orotic acid
  - id: CHEBI:76931
    label: N-acetylaspartylglutamate
  - id: CHEBI:30794
    label: Malonic acid
  - id: CHEBI:30860
    label: Methylmalonic acid
  - id: CHEBI:16856
    label: GSH
  - id: CHEBI:17858
    label: GSSG
  - id: CHEBI:30145
    label: lithium
  - id: MONDO:0019046
    label: leukodystrophies
  - id: MAXO:0000127
    label: genetic testing
  - id: MAXO:0009004
    label: whole exome sequencing (WES)
  - id: MAXO:0000079
    label: genetic counseling
  - id: HP:0000256
    label: Macrocephaly
  - id: HP:0001249
    label: Mental retardation
  - id: HP:0001252
    label: Hypotonia
  - id: CHEBI:21547
    label: N-acetylaspartic acid
  - id: CHEBI:27881
    label: Resveratrol (RSV)
  - id: HP:0001355
    label: Megalencephaly
  - id: HP:0001263
    label: Developmental delay
  - id: MAXO:0000068
    label: Transplantation
  - id: MONDO:0011925
    label: merosin-negative congenital muscular dystrophy
  - id: MAXO:0000387
    label: muscle biopsy
  - id: HP:0002350
    label: cerebellar cysts
  - id: CHEBI:33375
    label: gadolinium
  - id: HP:0001250
    label: Seizures
  - id: HP:0000750
    label: Speech delay
  - id: CHEBI:15354
    label: Choline
  - id: MONDO:0019262
    label: Batten disease
  - id: MONDO:0005180
    label: Parkinson's disease
  - id: MONDO:0008752
    label: Alexander disease
  - id: MONDO:0011380
    label: CACH/VWM
  - id: HP:0003819
    label: death in childhood
  - id: HP:0000407
    label: sensorineural hearing loss
  - id: MONDO:0010100
    label: Tay-Sachs disease
  - id: MONDO:0008876
    label: Bloom syndrome
  - id: MONDO:0009061
    label: cystic fibrosis
  - id: MONDO:0009131
    label: familial dysautonomia
  - id: MONDO:0009653
    label: mucolipidosis type IV
  - id: HP:0010864
    label: severe mental retardation
  - id: CHEBI:73688
    label: N-acetylaspartylglutamic acid
  - id: HP:0002415
    label: Leukodystrophies
  - id: HP:0003269
    label: Pelizaeus-Merzbacher disease
  - id: MONDO:0005648
    label: Autosomal recessive (AR) conditions; Autosomal dominant (AD) conditions;
      X-linked (XL) conditions
  - id: MAXO:0000530
    label: Genetic carrier screening
  - id: MONDO:0005071
    label: neurologic disease
  - id: CHEBI:9661
    label: Glyceryl triacetate
  - id: CHEBI:30089
    label: Acetate
  - id: CHEBI:22660
    label: Aspartic acid
  - id: MAXO:0009003
    label: preimplantation genetic diagnosis (PGD)
  - id: CHEBI:15366
    label: Acetic acid
  - id: CHEBI:18237
    label: Glutamic acid
  - id: MAXO:0001001
    label: gene therapy
  - id: CHEBI:157802
    label: Creatine (Cr)
  - id: CHEBI:53620
    label: Myo-Inositol (mI)
  - id: CHEBI:24996
    label: Lactate
  - id: CHEBI:16813
    label: Galactitol
  - id: CHEBI:22918
    label: Branched chain amino acids
  - id: MONDO:0018660
    label: Hemophilia
  - id: MONDO:0013282
    label: Alpha-1-antitrypsin Deficiency
  - id: CHEBI:17053
    label: l-aspartic acid
  - id: HP:0000952
    label: Jaundice
  - id: HP:0001942
    label: Metabolic acidosis
  - id: HP:0012734
    label: Ketotic hypoglycemia
  - id: HP:0001987
    label: Hyperammonemia
  - id: CHEBI:132943
    label: Aspartate
  - id: HP:0000618
    label: vision impairment
  - id: HP:0001141
    label: severe vision loss
  - id: HP:0000510
    label: Retinitis pigmentosa
  - id: HP:0032988
    label: Head lag
  - id: HP:0001257
    label: Spasticity
  - id: CHEBI:29987
    label: Glutamate
  - id: CHEBI:16865
    label: GABA
  - id: HP:0001276
    label: Increased muscle tone
  - id: HP:0025464
    label: oxidative stress
  - id: CHEBI:16240
    label: Hydrogen peroxide
  - id: MAXO:0000016
    label: cell therapy
  - id: HP:0012447
    label: Abnormal myelination
  - id: MONDO:0021042
    label: glioma
  - id: CHEBI:45716
    label: Vorinostat (SAHA)
  - id: CHEBI:72564
    label: Temozolomide (TMZ)
  - id: HP:0009733
    label: glioma
  - id: HP:0002383
    label: Brain inflammation
  - id: HP:0002421
    label: Poor head control
  - id: HP:0003808
    label: Abnormal muscle tone
  - id: HP:0000648
    label: Optic atrophy
  - id: CHEBI:15347
    label: Acetone
  - id: CHEBI:15377
    label: Water
  - id: CHEBI:30751
    label: Formic acid
  - id: MONDO:0000984
    label: Thalassemias
  - id: MONDO:0005066
    label: Metabolic disorders
  - id: HP:0008936
    label: axial hypotonia
  - id: HP:0001264
    label: spastic diplegia
  - id: CHEBI:64735
    label: lithium citrate
  - id: HP:0000529
    label: Progressive visual loss
  - id: HP:0000639
    label: Nystagmus
  - id: MONDO:0008090
    label: Diseases of the central nervous system (CNS)
  - id: MONDO:0016063
    label: Canavan disease (CD)
  - id: MAXO:0000144
    label: histological examination
